Project Description
Stemsight
Curing blindness with regenerative cell therapies
StemSight’s first target indication is limbal stem cell deficiency (LSCD), a severe rare disease of the cornea currently without valid treatment options for patients suffering from LSCD in both eyes. StemSight’s off-the-shelf cell therapy product could provide these patients with a cure to regain their vision.
Stemsight is based in Tampere, Finland and is headed by founder and CEO Laura Koivusalo.
Stemsight joined NOME in 2022.
